"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Descriptor ID |
D018796
|
MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 2 | 0 | 2 |
1996 | 5 | 0 | 5 |
1997 | 6 | 0 | 6 |
1998 | 6 | 0 | 6 |
1999 | 7 | 0 | 7 |
2000 | 7 | 0 | 7 |
2001 | 10 | 0 | 10 |
2002 | 6 | 0 | 6 |
2003 | 1 | 1 | 2 |
2004 | 1 | 2 | 3 |
2006 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 2 | 0 | 2 |
2017 | 0 | 1 | 1 |
2018 | 1 | 1 | 2 |
2019 | 3 | 0 | 3 |
2020 | 5 | 1 | 6 |
2021 | 2 | 0 | 2 |
2022 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
In Reply. Oncologist. 2022 Oct 01; 27(10):e827-e828.
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
-
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 04; 23(4):540-552.
-
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist. 2022 03 11; 27(3):e223-e232.
-
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol. 2022 06 10; 40(17):1939-1948.
-
A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. Adv Sci (Weinh). 2022 01; 9(2):e2103240.
-
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.
-
Risk Minimization of Antibody-Drug Conjugates in Oncology: A Review. Drug Saf. 2021 07; 44(7):733-742.
-
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3556-3566.
-
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 08; 95:106385.